New dosing strategy aims to reduce eye side effects in myeloma treatment
NCT ID NCT07614360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple myeloma who have had at least two prior treatments will be randomly assigned to different dosing regimens. The study will compare eye side effects and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin, bortezomib, and dexamethasone
What this could lead to
If successful, this could lead to a safer and more effective dosing schedule for this combination therapy, potentially improving outcomes for people with relapsed multiple myeloma.
What could go wrong
This is a phase 2 trial with only 150 participants, so results may not apply to everyone. The drug combination can cause serious eye problems, and alternative dosing may not reduce this risk or maintain effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••